Clinical trials: Digestive System Diseases
Hepatic Encephalopathy, Urea Cycle Disorders
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
The purpose of this study is to determine the safety and tolerability of GT4P administered orally as a single dose, and twice daily for 7 consecutive days, to subjects with hepatic impairment with cirrhosis (Child-Pugh scores of…
- Trial name
- NCT00986895
- Testing
- HPN-100
- Where
- 2 sites in Ukraine
- Volunteers
- 32 people
- Sponsor
- Amgen
Gastroesophageal Reflux, GERD
Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Conditions
- Gastroesophageal Reflux, GERD, GORD
- Trial name
- NCT00261339
- Testing
- Pantoprazole
- Where
- 45 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Takeda
Ulcerative Colitis
A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.
The proposed study is a randomized, double-blind,placebo-controlled, multicenter phase II study to investigate the safety and efficacy of SHR0302 in patients with moderate to severe active ulcerative colitis.
- Trial name
- NCT03675477
- Testing
- SHR0302
- Where
- 67 sites in United States, China and 3 more
- Volunteers
- 164 people
- Sponsor
- Reistone Biopharma Company Limited
Stage IV Pancreatic Cancer
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2, multicenter, randomized, placebo-controlled…
- Trial name
- ALPINE (NCT01647828)
- Testing
- OMP-59R5, Gemcitabine, Nab-Paclitaxel
- Where
- 26 sites in United States
- Volunteers
- 217 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Hepatitis C Virus Infection
Expanded Access to Glecaprevir/ Pibrentasvir
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency.
- Trial name
- NCT03123965
- Testing
- glecaprevir, pibrentasvir
- Where
- Slovenia
- Sponsor
- AbbVie
Hepatitis C
Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C
The study is a first in man, dose escalation study that will measure the safety and efficacy of TT-034 in the treatment of patients with chronic hepatitis C. The study is divided into 5 dose levels.
- Trial name
- NCT01899092
- Testing
- TT-034
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Tacere Therapeutics, Inc.
GERD (Gastroesophageal Reflux Disease)
An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients
This study aims to evaluate the status of AE and improvement effect of K-CAB Tab/K-CAB ODT(Tegoprazan) 50mg in patients with GERD.
- Trial name
- NCT07678177
- Where
- South Korea
- Volunteers
- 5,384 people
- Sponsor
- HK inno.N Corporation
Chronic Hepatitis B Virus Infection
Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection
Study HH006-202 is designed to assesses the efficacy and safety of HH-006 in adults chronic HBV infection. Eligible participants will receive study treatment for 48 weeks.
- Trial name
- NCT07519330
- Testing
- HH-006
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Huahui Health
Primary Sclerosing Cholangitis (PSC)
A POC and Dose-Ranging Study of HTD1801 in PSC Patients
The study was a dose-ranging, 18-week study comparing two doses of HTD1801 (500 mg BID and 1000 mg BID) to placebo in adult subjects with PSC.
- Trial name
- NCT03333928
- Testing
- HTD1801
- Where
- 26 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Chronic Hepatitis B
Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects
This study will assess the efficacy of ABF656 in chronic hepatitis B characterized by HBeAg positivity. The study is designed to establish a dose response and safety relationship sufficient to allow the subsequent design and…
- Trial name
- NCT00964665
- Testing
- albinterferon alfa-2b, Pegasys®
- Where
- 12 sites in China, Hong Kong and 3 more
- Volunteers
- 141 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C Virus
Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)
This was an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) in treatment-naive participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection.
- Trial name
- NCT02105467
- Testing
- Grazoprevir 100mg / Elbasvir 50 mg FDC
- Volunteers
- 421 people
- Sponsor
- Merck Sharp & Dohme LLC
Tricuspid Regurgitation
Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™
The TriCinch System™ is intended for percutaneous treatment of tricuspid regurgitation. It is a percutaneous catheter-based device designed for tricuspid valve repair in order to decrease effective cross-sectional area and…
- Trial name
- PREVENT (NCT02098200)
- Testing
- TriCinch System
- Where
- 14 sites in France, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- 4Tech Cardio Ltd.
HCC, Hepatitis B Virus Related Hepatocellular Carcinoma
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
- Conditions
- HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT06617000
- Testing
- SCG101
- Where
- 7 sites in China
- Volunteers
- 38 people
- Sponsor
- SCG Cell Therapy Pte. Ltd.
Pancreatic Cancer
A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.
- Trial name
- NCT02021500
- Testing
- ABI-007
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- Celgene
Ulcerative Colitis
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).
- Trial name
- LUCENT 2 (NCT03524092)
- Testing
- Mirikizumab SC, Mirikizumab IV
- Where
- 385 sites in United States, Argentina and 32 more
- Volunteers
- 1,328 people
- Sponsor
- Eli Lilly and Company
Hepatitis B, Chronic
Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients
The purpose of this study is to evaluate the antiviral activity and safety of EntecaBell ODT. in chronic hepatitis B Patients.
- Trial name
- NCT02588937
- Testing
- EntecaBell ODT. 0.5mg, Baraclude Tab. 0.5mg
- Where
- 9 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- Chong Kun Dang Pharmaceutical
NASH - Nonalcoholic Steatohepatitis
Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials
This is a companion study assessing the ¹³C-Methacetin Breath Test (MBT) in subjects participating in the Bristol Myers-Squibb (BMS) NCT03486899 and NCT03486912 referenced studies using study drug BMS-986036.
- Trial name
- NCT03611101
- Testing
- ¹³C-Methacetin Breath Test, BMS-986036, BreathID MCS device
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Meridian Bioscience, Inc.
Crohn's Disease
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)
The purpose of this study is to evaluate the combined remission of complex perianal fistulas, defined as the clinical assessment at Week 24 of closure of all treated external openings that were draining at baseline despite gentle…
- Trial name
- ADMIRE-CD-II (NCT03279081)
- Testing
- Cx601
- Where
- 159 sites in United States, Belgium and 13 more
- Volunteers
- 568 people
- Sponsor
- Tigenix S.A.U.
Crohn's Disease
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
- Trial name
- NCT03105128
- Testing
- risankizumab IV, risankizumab SC
- Where
- 475 sites in United States, Argentina and 42 more
- Volunteers
- 931 people
- Sponsor
- AbbVie
Fibromyalgia
Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia
Fibromyalgia is a medical disorder characterized by chronic widespread pain, and a heightened and painful response to pressure. Fibromyalgia symptoms are not restricted to pain, leading to the use of the alternative term…
- Trial name
- L2009-03 (NCT01469936)
- Testing
- PERMEAPROTECT
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Lescuyer Laboratory